WHWK
Whitehawk Therapeutics Inc
NASDAQ · USHealthcareBiotechnology
$3.79-2.57%
Price as of Jul 20, 2026
WHWK financials
Whitehawk Therapeutics Inc financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $7.1M | $26.0M | $24.4M | $15.2M |
| Cost of revenue | $760.0K | $54.1M | $51.7M | $34.0M |
| Gross profit | $6.4M | -$28.1M | -$27.4M | -$18.8M |
| Operating expenses | $120.8M | $39.4M | $44.5M | $43.9M |
| Operating income | -$114.4M | -$67.5M | -$71.9M | -$62.7M |
| Net income | -$20.6M | -$63.7M | -$65.8M | -$60.5M |
| EBITDA | -$20.5M | -$64.6M | -$65.4M | -$58.8M |
| Basic EPS | $-0.33 | $-2.36 | $-2.44 | $-2.69 |
| Diluted EPS | $-0.33 | $-2.36 | $-2.44 | $-2.69 |
| Balance sheet | ||||
| Cash & equivalents | $37.6M | $28.7M | $62.9M | $39.0M |
| Total assets | $150.8M | $70.3M | $132.4M | $184.2M |
| Total liabilities | $14.5M | $17.8M | $27.2M | $25.9M |
| Stockholders’ equity | $136.3M | $52.5M | $105.2M | $158.4M |
| Total debt | $0.00 | $833.0K | $1.3M | $1.7M |
| Net debt | -$37.6M | -$27.8M | -$61.6M | -$37.4M |
| Cash flow | ||||
| Operating cash flow | -$97.4M | -$59.5M | -$59.7M | -$49.6M |
| Capital expenditure | -$552.0K | -$1.7M | -$4.0M | -$444.0K |
| Free cash flow | -$98.0M | -$61.2M | -$63.6M | -$50.1M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |